BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Savara Inc. ("Savara†or the "Company†) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES F. ...

Accessibility StatementSkip Navigation https://zlk.com/pslra-1/savara-inc-lawsuit-submission-form?prid=167315&wire=4 SVRA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) a ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=166911&from=3 CLASS PERIOD: March 4, 2024 to May ...

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Savara Inc. (SVRA) Investors To Inquire About Securities Fraud Class Action. ...

公司核心产品与业务 - Savara Inc 是一家专注于罕见呼吸系统疾病的临床阶段生物制药公司 [1] - 公司主要候选产品为MOLBREEVI（也称为molgramostim） 这是一种吸入性粒细胞-巨噬细胞集落刺激因子（GM-CSF）[1] 集体诉讼指控内容 - 指控公司在2024年3月7日至2025年5月23日期间误导投资者关于主要候选药物的可行性 [1][2] - 指控未能披露MOLBREEVI生物制剂许可申请缺乏足够的化学、制造和控制信息 [2] - 指控未能披露FDA不太可能以当前形式批准MOLBREEVI的BLA申请 [2] - 指控公司不太可能按向投资者表示的时间框架完成MOLBREEVI的BLA提交 [2] - 指控监管批准延迟增加了公司需要筹集额外资金的可能性 [2] FDA监管回应与市场反应 - 2025年5月27日公司宣布收到FDA拒绝提交（RTF）信件 涉及MOLBREEVI治疗aPap患者的BLA申请 [3] - FDA初步审查确定申请材料不够完整 无法进行实质性审查 要求提供额外的化学、制造和控制相关数据 [3] - 此消息导致公司股价下跌0.90美元/股 跌幅达31.69% 2025年5月27日收盘价为1.94美元/股 [3]

LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Savara, Inc., ("Savara" or the "Company") (NASDAQ: SVRA) investors of a class action on behalf of investors that bought securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). Savara investors have until November 7th, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Savara Inc. ("Savara†or the "Company†) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the "Class Period†). Savara investors have until November 7, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE. ...

LOS ANGELES--(BUSINESS WIRE)---- $SVRA--SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm. ...

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Savara securitie ...

法律诉讼概况 - Pomerantz LLP宣布对Savara Inc及其部分高管提起集体诉讼，诉讼在美国宾夕法尼亚州东区地方法院进行，案件编号为25-cv-05147 [1] - 该集体诉讼代表在2024年3月7日至2025年5月23日期间购买或收购Savara证券的所有个人和实体，指控被告违反联邦证券法 [1] - 符合资格的投资者需在2025年11月7日前向法院申请成为首席原告 [2] 公司业务与产品管线 - Savara是一家专注于罕见呼吸系统疾病的临床阶段生物制药公司，其主要候选产品是MOLBREEVI，一种吸入性粒细胞-巨噬细胞集落刺激因子 [4] - MOLBREEVI正处于治疗自身免疫性肺泡蛋白沉积症的3期IMPALA-2关键临床试验中，该疾病是一种慢性、使人衰弱的罕见肺部疾病 [4] - 公司曾表示基于对MOLBREEVI的投资及其“稳健的财政纪律记录”，其资金充足状态最早可维持至2026年，最晚至2027年下半年 [4] 监管申请与问题 - 2024年12月，Savara开始向美国FDA滚动提交MOLBREEVI的生物制品许可申请，用于治疗aPAP [5] - 公司在宣布提交申请的新闻稿中强调，基于3期IMPALA-2试验的阳性结果，相信MOLBREEVI显示出良好的获益-风险特征，并预计在2025年第一季度末完成BLA的提交 [5] - 起诉书指控，在整个集体诉讼期间，被告就公司业务、运营和前景做出了重大虚假和误导性陈述，包括MOLBREEVI的BLA在化学、制造和控制方面信息不足，导致FDA不太可能批准其当前形式的申请 [6] 监管挫折与市场反应 - 2025年5月27日，Savara宣布收到FDA的拒收函，FDA初步审查认为BLA不够完整，无法进行实质性审查，并要求提供额外的CMC相关数据 [7] - 同日，Guggenheim发布报告，将Savara的目标股价从9美元下调至8美元，并表示不预计公司在2028年前能持续盈利，且公司可能通过二次发行股票等方式筹集额外资金 [8] - Guggenheim报告预测CMC延迟可能导致MOLBREEVI的生产策略变更，预计市场推出将推迟至2027年初，比最初预期晚一年 [8] - 受此消息影响，Savara股价在2025年5月27日下跌0.90美元，跌幅达31.69%，收于每股1.94美元 [9] 财务与运营更新 - 2025年8月13日，Savara公布2025年第二季度财务业绩，透露公司计划在2025年12月重新提交MOLBREEVI的BLA，这与之前表示将在2025年第一季度完成提交的说法相反 [10]